التفاصيل البيبلوغرافية
| العنوان: |
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. |
| المؤلفون: |
Duell, Johannes, Obr, Aleš, Augustin, Marinela, Endell, Jan, Liu, Hao, Geiger, Sabine, Silverman, Ian M., Ambarkhane, Sumeet, Rosenwald, Andreas |
| المصدر: |
Leukemia & Lymphoma; Feb 2022, Vol. 63 Issue 2, p468-472, 5p |
| مصطلحات موضوعية: |
CD19 antigen, DIFFUSE large B-cell lymphomas, LENALIDOMIDE, MANTLE cell lymphoma, ANTIBODY-dependent cell cytotoxicity |
| مستخلص: |
This contrasts with reports of CD19 expression loss after bispecific anti-CD19 treatment and CD19-directed CAR T-cell treatments [[7]]. CD19 is an important target for novel anti-lymphoma treatments as it is broadly and homogenously expressed across many B-cell malignancies [[1]]. DNA and RNA analyses did not find evidence for CD19 mutations, dominant exon skipping or loss of CD19 mRNA expression, which would be indicative of resistance to further CD19-targeted therapy. [Extracted from the article] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
